Table of Contents Author Guidelines Submit a Manuscript
Journal of Aging Research
Volume 2012 (2012), Article ID 251217, 11 pages
http://dx.doi.org/10.1155/2012/251217
Review Article

Novel Intriguing Strategies Attenuating to Sarcopenia

1Research Center for Physical Fitness, Sports and Health, Toyohashi University of Technology, 1-1 Hibarigaoka, Tenpaku-cho, Toyohashi 441-8580, Japan
2School of Dentistry, Health Sciences University of Hokkaido, Kanazawa, Ishikari-Tobetsu, Hokkaido 061-0293, Japan

Received 29 July 2011; Accepted 25 November 2011

Academic Editor: Olivier Guérin

Copyright © 2012 Kunihiro Sakuma and Akihiko Yamaguchi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. G. Candow and P. D. Chilibeck, “Differences in size, strength, and power of upper and lower body muscle groups in young and older men,” Journals of Gerontology Series A: Biological Science Medical Science, vol. 60, no. 2, pp. 148–156, 2005. View at Google Scholar · View at Scopus
  2. L. J. Melton 3rd, S. Khosla, C. S. Crowson, W. M. O'Fallon, and B. L. Riggs, “Epidemiology of sarcopenia,” Journal of the American Geriatrics Society, vol. 48, no. 6, pp. 625–630, 2000. View at Google Scholar · View at Scopus
  3. R. N. Baumgartner, D. L. Waters, D. Gallagher, J. E. Morley, and P. J. Garry, “Predictors of skeletal muscle mass in elderly men and women,” Mechanisms of Ageing and Development, vol. 107, no. 2, pp. 123–136, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. E. T. Poehlnan, M. J. Toth, and T. Fonong, “Exercise, substrate utilization and energy requirements in the elderly,” International Journal of Obesity, vol. 19, no. 4, pp. S93–S96, 1995. View at Google Scholar
  5. R. D. Griffiths, “Muscle mass, survival, and the elderly ICU patient,” Nutrition, vol. 12, no. 6, pp. 456–458, 1996. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Janssen, D. S. Shepard, P. T. Katzmarzyk, and R. Roubenoff, “The healthcare costs of sarcopenia in the United States,” Journal of the American Geriatrics Society, vol. 52, no. 1, pp. 80–85, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. K. R. Short and K. S. Nair, “The effect of age on protein metabolism,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 3, no. 1, pp. 39–44, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. K. R. Short, J. L. Vittone, J. L. Bigelow, D. N. Proctor, and K. S. Nair, “Age and aerobic exercise training effects on whole body and muscle protein metabolism,” American Journal of Physiology: Endocrinology and Metabolism, vol. 286, no. 1, pp. E92–E101, 2004. View at Google Scholar · View at Scopus
  9. J. Lexell, “Human aging, muscle mass, and fiber type composition,” Journals of Gerontology Series A: Biological Science and Medical Science, vol. 50, pp. 11–16, 1995. View at Google Scholar · View at Scopus
  10. L. Larsson, “Morphological and functional characteristics of the ageing skeletal muscle in man. A cross-sectional study,” Acta Physiologica Scandinavica, Supplement, vol. 457, pp. 1–36, 1978. View at Google Scholar · View at Scopus
  11. L. Larsson, B. Sjödin, and J. Karlsson, “Histochemical and biochemical changes in human skeletal muscle with age in sedentary males age 22-65 years,” Acta Physiologica Scandinavica, vol. 103, no. 1, pp. 31–39, 1978. View at Google Scholar · View at Scopus
  12. L. B. Verdijk, R. Koopman, G. Schaart, K. Meijer, H. H. Savelberg, and L. J. van Loon, “Satellite cell content is specifically reduced in type II skeletal muscle fibers in the elderly,” American Journal of Physiology: Endocrinology and Metabolism, vol. 292, no. 1, pp. E151–E157, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. L. B. Verdijk, B. G. Gleeson, R. A. M. Jonkers et al., “Skeletal muscle hypertrophy following resistance training is accompanied by a fiber type-specific increase in satellite cell content in elderly men,” Journals of Gerontology Series A: Biological Science and Medical Sciences, vol. 64, no. 3, pp. 332–339, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. A. S. Brack, H. Bildsoe, and S. M. Hughes, “Evidence that satellite cell decrement contributes to preferential decline in nuclear number from large fibres during murine age-related muscle atrophy,” Journal of Cell Science, vol. 118, no. 20, pp. 4813–4821, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. C. A. Collins, P. S. Zammit, A. P. Ruiz, J. E. Morgan, and T. A. Partridge, “A population of myogenic stem cells that survives skeletal muscle aging,” Stem Cells, vol. 25, no. 4, pp. 885–894, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Day, G. Shefer, A. Shearer, and Z. Yablonka-Reuveni, “The depletion of skeletal muscle satellite cells with age is concomitant with reduced capacity of single progenitors to produce reserve progeny,” Developmental Biology, vol. 340, no. 2, pp. 330–343, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Shefer, D. P. van de Mark, J. B. Richardson, and Z. Yablonka-Reuveni, “Satellite-cell pool size does matter: defining the myogenic potency of aging skeletal muscle,” Developmental Biology, vol. 294, no. 1, pp. 50–66, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. I. M. Conboy, M. J. Conboy, G. M. Smythe, and T. A. Rando, “Notch-mediated restoration of regenerative potential to aged muscle,” Science, vol. 302, no. 5650, pp. 1575–1577, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. S. M. Roth, G. F. Martel, F. M. Ivey et al., “Skeletal muscle satellite cell populations in healthy young and older men and women,” Anatomical Record, vol. 260, no. 4, pp. 351–358, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. A. J. Wagers and I. M. Conboy, “Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis,” Cell, vol. 122, no. 5, pp. 659–667, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Lexell, “Ageing and human muscle: observations from Sweden,” Canadian Journal of Applied Physiology, vol. 18, no. 1, pp. 2–18, 1993. View at Google Scholar · View at Scopus
  22. R. Roubenoff and V. A. Hughes, “Sarcopenia: current concepts,” Journals of Gerontology Series A: Biologial Science and Medical Science, vol. 55, no. 12, pp. M716–M724, 2000. View at Google Scholar · View at Scopus
  23. K. Sakuma, M. Akiho, H. Nakashima, H. Akima, and M. Yasuhara, “Age-related reductions in expression of serum response factor and myocardin-related transcription factor A in mouse skeletal muscles,” Biochimica et Biophysica Acta Molecular Basis of Disease, vol. 1782, no. 7-8, pp. 453–461, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Sakuma and A. Yamaguchi, “Molecular mechanisms in aging and current strategies to counteract sarcopenia,” Current Aging Science, vol. 3, no. 2, pp. 90–101, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Sakuma and A. Yamaguchi, “Sarcopenia: molecular mechanisms and current therapeutic strategy,” in Cell Aging, Nova Science Publishers, Huntington, NY, USA, 2011. View at Google Scholar
  26. D. Paddon-Jones and B. B. Rasmussen, “Dietary protein recommendations and the prevention of sarcopenia,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 12, no. 1, pp. 86–90, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Bradley, P. J. Yaworsky, and F. S. Walsh, “Myostatin as a therapeutic target for musculoskeletal disease,” Cellular and Molecular Life Sciences, vol. 65, no. 14, pp. 2119–2124, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Sakuma and A. Yamaguchi, “Inhibitors of myostatin- and proteasome-dependent signaling for attenuating muscle wasting,” Recent Patents on Regenerative Medicine, vol. 1, no. 3, pp. 284–298, 2011. View at Google Scholar
  29. S. D. Kunkel, M. Suneja, S. M. Ebert et al., “mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass,” Cell Metabolism, vol. 13, no. 6, pp. 627–638, 2011. View at Publisher · View at Google Scholar
  30. G. I. Smith, P. Atherton, D. N. Reeds et al., “Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial,” American Journal of Clinical Nutrition, vol. 93, no. 2, pp. 402–412, 2011. View at Publisher · View at Google Scholar
  31. A. C. McPherron, A. M. Lawler, and S. J. Lee, “Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member,” Nature, vol. 387, no. 6628, pp. 83–90, 1997. View at Google Scholar · View at Scopus
  32. S. J. Lee, “Regulation of muscle mass by myostatin,” Annual Review of Cell and Developmental Biology, vol. 20, pp. 61–86, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Langley, M. Thomas, A. Bishop, M. Sharma, S. Gilmour, and R. Kambadur, “Myostatin inhibits myoblast differentiation by down-regulating MyoD expression,” Journal of Biological Chemistry, vol. 277, no. 51, pp. 49831–49840, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Thomas, B. Langley, C. Berry et al., “Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast differentiation,” Journal of Biological Chemistry, vol. 275, no. 51, pp. 40235–40243, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. W. Yang, Y. Zhang, Y. Li, Z. Wu, and D. Zhu, “Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3β pathway and is antagonized by insulin-like growth factor 1,” Journal of Biological Chemistry, vol. 282, no. 6, pp. 3799–3808, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. A. C. McPherron and S. J. Lee, “Double muscling in cattle due to mutations in the myostatin gene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 23, pp. 12457–12461, 1997. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Schuelke, K. R. Wagner, L. E. Stolz et al., “Myostatin mutation associated with gross muscle hypertrophy in a child,” New England Journal of Medicine, vol. 350, no. 26, pp. 2682–2688, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. D. L. Allen and T. G. Unterman, “Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors,” American Journal of Physiology: Cell Physiology, vol. 292, no. 1, pp. C188–C199, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Léger, W. Derave, K. de Bock, P. Hespel, and A. P. Russell, “Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation,” Rejuvenation Research, vol. 11, no. 1, pp. 163–175, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. M. E. Carlson, M. Hsu, and I. M. Conboy, “Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells,” Nature, vol. 454, no. 7203, pp. 528–532, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Haddad and G. R. Adams, “Aging-sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophy,” Journal of Applied Physiology, vol. 100, no. 4, pp. 1188–1203, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Bogdanovich, T. O. Krag, E. R. Barton et al., “Functional improvement of dystrophic muscle by myostatin blockade,” Nature, vol. 420, no. 6914, pp. 418–421, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. E. L. Holzbaur, D. S. Howland, N. Weber et al., “Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis,” Neurobiology of Disease, vol. 23, no. 3, pp. 697–707, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. K. R. Wagner, J. L. Fleckenstein, A. A. Amato et al., “A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy,” Annals of Neurology, vol. 63, no. 5, pp. 561–571, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. V. Siriett, L. Platt, M. S. Salerno, N. Ling, R. Kambadur, and M. Sharma, “Prolonged absence of myostatin reduces sarcopenia,” Journal of Cellular Physiology, vol. 209, no. 3, pp. 866–873, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. N. K. LeBrasseur, T. M. Schelhorn, B. L. Bernardo, P. G. Cosgrove, P. M. Loria, and T. A. Brown, “Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice,” Journals of Gerontology Series A: Biological Science and Medical Sciences, vol. 64, no. 9, pp. 940–948, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. K. T. Murphy, R. Koopman, T. Naim et al., “Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function,” FASEB Journal, vol. 24, no. 11, pp. 4433–4442, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Welle, K. Burgess, and S. Mehta, “Stimulation of skeletal muscle myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6 phosphorylation by inhibition of myostatin in mature mice,” American Journal of Physiology: Endocrinology and Metabolism, vol. 296, no. 3, pp. E567–E572, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Amirouche, A. C. Durieux, S. Banzet et al., “Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle,” Endocrinology, vol. 150, no. 1, pp. 286–294, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. C. McFarlane, E. Plummer, M. Thomas et al., “Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism,” Journal of Cellular Physiology, vol. 209, no. 2, pp. 501–514, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. I. Chelh, B. Meunier, B. Picard et al., “Molecular profiles of Quadriceps muscle in myostatin-null mice reveal PI3K and apoptotic pathways as myostatin targets,” BMC Genomics, vol. 10, article 196, 13 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. R. T. S. Frighetto, R. M. Welendorf, E. N. Nigro, N. Frighetto, and A. C. Siani, “Isolation of ursolic acid from apple peels by high speed counter-current chromatography,” Food Chemistry, vol. 106, no. 2, pp. 767–771, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Liu, “Pharmacology of oleanolic acid and ursolic acid,” Journal of Ethnopharmacology, vol. 49, no. 2, pp. 57–68, 1995. View at Publisher · View at Google Scholar · View at Scopus
  54. Z. H. Wang, C. C. Hsu, C. N. Huang, and M. C. Yin, “Anti-glycative effects of oleanolic acid and ursolic acid in kidney of diabetic mice,” European Journal of Pharmacology, vol. 628, no. 1–3, pp. 255–260, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Liu, “Oleanolic acid and ursolic acid: research perspectives,” Journal of Ethnopharmacology, vol. 100, no. 1-2, pp. 92–94, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. W. Zhang, D. Hong, Y. Zhou et al., “Ursolic acid and its derivative inhibit protein tyrosine phosphatase 1B, enhancing insulin receptor phosphorylation and stimulating glucose uptake,” Biochimica et Biophysica Acta, vol. 1760, no. 10, pp. 1505–1512, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. K. A. Kenner, E. Anyanwu, J. M. Olefsky, and J. Kusari, “Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling,” Journal of Biological Chemistry, vol. 271, no. 33, pp. 19810–19816, 1996. View at Publisher · View at Google Scholar · View at Scopus
  58. L. M. Arterburn, E. B. Hall, and H. Oken, “Distribution, interconversion, and dose response of n-3 fatty acids in humans,” American Journal of Clinical Nutrition, vol. 83, no. 6, pp. 1467S–1476S, 2006. View at Google Scholar · View at Scopus
  59. K. C. Fearon, M. F. von Meyenfeldt, A. G. Moses et al., “Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial,” Gut, vol. 52, no. 10, pp. 1479–1486, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. C. R. Harper and T. A. Jacobson, “Usefulness of omega-3 fatty acids and the prevention of coronary heart disease,” American Journal of Cardiology, vol. 96, no. 11, pp. 1521–1529, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. R. J. Bloomer, D. E. Larson, K. H. Fisher-Wellman, A. J. Galpin, and B. K. Schilling, “Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study,” Lipids in Health and Disease, vol. 8, article 36, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. T. A. Babcock, W. S. Helton, and N. J. Espat, “Eicosapentaenoic acid (EPA): an antiinflammatory ω-3 fat with potential clinical applications,” Nutrition, vol. 16, no. 11-12, pp. 1116–1118, 2000. View at Publisher · View at Google Scholar · View at Scopus
  63. P. Singer, H. Shapiro, M. Theilla, R. Anbar, J. Singer, and J. Cohen, “Anti-inflammatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective,” Intensive Care Medicine, vol. 34, no. 9, pp. 1580–1592, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. T. A. Babcock, W. S. Helton, D. Hong, and N. J. Espat, “Omega-3 fatty acid lipid emulsion reduces LPS-stimulated macrophage TNF-α production,” Surgical Infections, vol. 3, no. 2, pp. 145–149, 2002. View at Google Scholar · View at Scopus
  65. P. Magee, S. Pearson, and J. Allen, “The omega-3 fatty acid, eicosapentaenoic acid (EPA), prevents the damaging effects of tumour necrosis factor (TNF)-alpha during murine skeletal muscle cell differentiation,” Lipids in Health and Disease, vol. 7, article 24, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. R. V. Machado, A. F. Mauricio, A. P. T. Taniguti, R. Ferretti, H. S. Neto, and M. J. Marques, “Eicosapentaenoic acid decreases TNF-α and protects dystrophic muscles of mdx mice from degeneration,” Journal of Neuroimmunology, vol. 232, no. 1-2, pp. 145–150, 2011. View at Publisher · View at Google Scholar
  67. J. E. Fabre, A. Rivard, M. Magner, M. Silver, and J. M. Isner, “Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo,” Circulation, vol. 99, no. 23, pp. 3043–3049, 1999. View at Google Scholar · View at Scopus
  68. E. M. de Cavanagh, B. Piotrkowski, N. Basso et al., “Enalapril and losartan attenuate mitochondrial dysfunction in aged rats,” The FASEB Journal, vol. 17, no. 9, pp. 1096–1098, 2003. View at Google Scholar · View at Scopus
  69. M. Maggio, G. P. Ceda, F. Lauretani et al., “Relation of angiotensin converting enzyme inhibitor treatment to insulin-like growth factor-1 serum levels in subjects. 65 years of age (the InCHIANTI study),” American Journal of Cardiology, vol. 97, no. 10, pp. 1525–1529, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. G. Onder, B. W. J. H. Penninx, R. Balkrishnan et al., “Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study,” Lancet, vol. 359, no. 9310, pp. 926–930, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Dossegger, E. Aldor, M. G. Baird et al., “Influence of angiotensin converting enzyme inhibition on exercise performance and clinical symptoms in chronic heart failure—a multicentre, double-blind, placebo-controlled trial,” European Heart Journal, vol. 14, pp. 18–23, 1993. View at Google Scholar · View at Scopus
  72. G. D. Schellenbaum, N. L. Smith, S. R. Heckbert et al., “Weight loss, muscle strength, and angiotensin-converting enzyme inhibitors in older adults with congestive heart failure or hypertension,” Journal of the American Geriatrics Society, vol. 53, no. 11, pp. 1996–2000, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. D. Sumukadas, M. D. Witham, A. D. Struthers, and M. E. T. McMurdo, “Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial,” Canadian Medical Association Journal, vol. 177, no. 8, pp. 867–874, 2007. View at Publisher · View at Google Scholar
  74. G. Leonetti, C. Mazzola, C. Pasotti et al., “Treatment of hypertension in the elderly—effects on blood pressure, heart rate, and physical fitness,” American Journal of Medicine, vol. 90, pp. S12–S13, 1991. View at Google Scholar · View at Scopus
  75. D. Bunout, G. Barrera, P. M. de la Maza, L. Leiva, C. Backhouse, and S. Hirsch, “Effects of enalapril or nifedipine on muscle strength or functional capacity in elderly subjects. A double blind trial,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 10, no. 2, pp. 77–84, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. D. Cai, J. D. Frantz, N. E. Tawa Jr. et al., “IKKβ/NF-κB activation causes severe muscle wasting in mice,” Cell, vol. 119, no. 2, pp. 285–298, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. W. E. Mitch and A. L. Goldberg, “Mechanisms of disease: mechanisms of muscle wasting: the role of the ubiquitin-proteasome pathway,” New England Journal of Medicine, vol. 335, no. 25, pp. 1897–1905, 1996. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Sandri, C. Sandri, A. Gilbert et al., “Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy,” Cell, vol. 117, no. 3, pp. 399–412, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. T. N. Stitt, D. Drujan, B. A. Clarke et al., “The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors,” Molecular Cell, vol. 14, no. 3, pp. 395–403, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Bossola, F. Pacelli, P. Costelli, A. Tortorelli, F. Rosa, and G. B. Doglietto, “Proteasome activities in the rectus abdominis muscle of young and older individuals,” Biogerontology, vol. 9, no. 4, pp. 261–268, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. J. S. Pattison, L. C. Folk, R. W. Madsen, T. E. Childs, and F. W. Booth, “Transcriptional profiling identifies extensive downregulation of extracellular matrix gene expression in sarcopenic rat soleus muscle,” Physiological Genomics, vol. 15, pp. 34–43, 2004. View at Google Scholar · View at Scopus
  82. L. Combaret, D. Dardevet, D. Béchet, D. Taillandier, L. Mosoni, and D. Attaix, “Skeletal muscle proteolysis in aging,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 12, no. 1, pp. 37–41, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. K. C. DeRuisseau, A. N. Kavazis, and S. K. Powers, “Selective downregulation of ubiquitin conjugation cascade mRNA occurs in the senescent rat soleus muscle,” Experimental Gerontology, vol. 40, no. 6, pp. 526–531, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Welle, A. L. Brooks, J. M. Delehanty, N. Needler, and C. A. Thornton, “Gene expression profile of aging in human muscle,” Physiological Genomics, vol. 14, pp. 149–159, 2003. View at Google Scholar · View at Scopus
  85. S. A. Whitman, M. J. Wacker, S. R. Richmond, and M. P. Godard, “Contributions of the ubiquitin-proteasome pathway and apoptosis to human skeletal muscle wasting with age,” Pflügers Archiv European Journal of Physiology, vol. 450, no. 6, pp. 437–446, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Clavel, A. S. Coldefy, E. Kurkdjian, J. Salles, I. Margaritis, and B. Derijard, “Atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 are up-regulated in aged rat Tibialis Anterior muscle,” Mechanisms of Ageing and Development, vol. 127, no. 10, pp. 794–801, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. E. Edström, M. Altun, M. Hägglund, and B. Ulfhake, “Atrogin-1/MAFbx and MuRF1 are downregulated in aging-related loss of skeletal muscle,” Journals of Gerontology: Series A Biological Sciences and Medical Sciences, vol. 61, no. 7, pp. 663–674, 2006. View at Google Scholar · View at Scopus
  88. D. Attaix, L. Mosoni, D. Dardevet, L. Combaret, P. P. Mirand, and J. Grizard, “Altered responses in skeletal muscle protein turnover during aging in anabolic and catabolic periods,” International Journal of Biochemistry and Cell Biology, vol. 37, no. 10, pp. 1962–1973, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. A. D. Husom, E. A. Peters, E. A. Kolling, N. A. Fugere, L. V. Thompson, and D. A. Ferrington, “Altered proteasome function and subunit composition in aged muscle,” Archives of Biochemistry and Biophysics, vol. 421, no. 1, pp. 67–76, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. D. H. Lee, “Proteasome inhibitors: valuable new tools for cell biologists,” Trends in Cell Biology, vol. 8, no. 10, pp. 397–403, 1998. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Adams, V. J. Palombella, E. A. Sausville et al., “Proteasome inhibitors: a novel class of potent and effective antitumor agents,” Cancer Research, vol. 59, no. 11, pp. 2615–2622, 1999. View at Google Scholar · View at Scopus
  92. R. Z. Orlowski, “Proteasome inhibitors in cancer therapy,” Methods in Molecular Biology, vol. 100, pp. 197–203, 1997. View at Google Scholar
  93. G. Bonuccelli, F. Sotgia, E. Capozza, E. Gazzerro, C. Minetti, and M. P. Lisanti, “Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice,” Cell Cycle, vol. 6, no. 10, pp. 1242–1248, 2007. View at Google Scholar · View at Scopus
  94. E. Gazzerro, S. Assereto, A. Bonetto et al., “Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies,” American Journal of Pathology, vol. 176, no. 4, pp. 1863–1877, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. B. C. Beehler, P. G. Sleph, L. Benmassaoud, and G. J. Grover, “Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation,” Experimental Biology and Medicine, vol. 231, no. 3, pp. 335–341, 2006. View at Google Scholar · View at Scopus
  96. P. Bernardi, “Mitochondrial transport of cations: channels, exchangers, and permeability transition,” Physiological Reviews, vol. 79, no. 4, pp. 1127–1155, 1999. View at Google Scholar · View at Scopus
  97. N. Zamzami and G. Kroemer, “The mitochondrion in apoptosis: how Pandora's box opens,” Nature Reviews Molecular Cell Biology, vol. 2, no. 1, pp. 67–71, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. T. Nakagawa, S. Shimizu, T. Watanabe et al., “Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death,” Nature, vol. 434, no. 7033, pp. 652–658, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. A. C. Schinzel, O. Takeuchi, Z. Huang et al., “Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 34, pp. 12005–12010, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. D. P. Millay, M. A. Sargent, H. Osinska et al., “Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy,” Nature Medicine, vol. 14, no. 4, pp. 442–447, 2008. View at Publisher · View at Google Scholar · View at Scopus
  101. E. R. Wissing, D. P. Millay, G. Vuagniaux, and J. D. Molkentin, “Debio-025 is more effective than prednisone in reducing muscular pathology in mdx mice,” Neuromuscular Disorders, vol. 20, no. 11, pp. 753–760, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. T. Tiepolo, A. Angelin, E. Palma et al., “The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1-/-myopathic mice,” British Journal of Pharmacology, vol. 157, no. 6, pp. 1045–1052, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. C. Angelini, “The role of corticosteroids in muscular dystrophy: a critical appraisal,” Muscle and Nerve, vol. 36, no. 4, pp. 424–435, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. B. Balaban, D. J. Matthews, G. H. Clayton, and T. Carry, “Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy long-term effect,” American Journal of Physical Medicine and Rehabilitation, vol. 84, no. 11, pp. 843–850, 2005. View at Publisher · View at Google Scholar · View at Scopus
  105. M. R. Morissette, S. A. Cook, C. Buranasombati, M. A. Rosenberg, and A. Rosenzweig, “Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt,” American Journal of Physiology: Cell Physiology, vol. 297, no. 5, pp. C1124–C1132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  106. A. U. Trendelenburg, A. Meyer, D. Rohner, J. Boyle, S. Hatakeyama, and D. J. Glass, “Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size,” American Journal of Physiology: Cell Physiology, vol. 296, no. 6, pp. C1258–C1270, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. K. E. Wellen and C. B. Thompson, “Cellular metabolic stress: considering how cells respond to nutrient excess,” Molecular Cell, vol. 40, no. 2, pp. 323–332, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. J. O. Holloszy, “Regulation by exercise of skeletal muscle,” Journal of Physiology and Pharmacology, vol. 59, no. 7, pp. 5–18, 2008. View at Google Scholar · View at Scopus
  109. A. J. Dirks and C. Leeuwenburgh, “Aging and lifelong calorie restriction result in adaptations of skeletal muscle apoptosis repressor, apoptosis-inducing factor, X-linked inhibitor of apoptosis, caspase-3, and caspase-12,” Free Radical Biology and Medicine, vol. 36, no. 1, pp. 27–39, 2004. View at Publisher · View at Google Scholar · View at Scopus
  110. G. López-Lluch, N. Hunt, B. Jones et al., “Calorie restriction induces mitochondrial biogenesis and bioenergetic efficiency,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 6, pp. 1768–1773, 2006. View at Publisher · View at Google Scholar · View at Scopus
  111. A. M. Payne, S. L. Dodd, and C. Leeuwenburgh, “Life-long calorie restriction in Fischer 344 rats attenuates age-related loss in skeletal muscle-specific force and reduces extracellular space,” Journal of Applied Physiology, vol. 95, no. 6, pp. 2554–2562, 2003. View at Google Scholar · View at Scopus
  112. T. Philips and C. Leeuwenburgh, “Muscle fiber specific apoptosis and TNF-α signaling in sarcopenia are attenuated by life-long calorie restriction,” FASEB Journal, vol. 19, no. 6, pp. 668–670, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. D. R. Taaffe, “Sarcopenia—exercise as a treatment strategy,” Australian Family Physician, vol. 35, no. 3, pp. 130–134, 2006. View at Google Scholar · View at Scopus
  114. E. Marzetti, H. A. Lees, S. E. Wohlgemuth, and C. Leeuwenburgh, “Sarcopenia of aging: underlying cellular mechanisms and protection by calorie restriction,” BioFactors, vol. 35, no. 1, pp. 28–35, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. M. Sandri, J. Lin, C. Handschin et al., “PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 44, pp. 16260–16265, 2006. View at Publisher · View at Google Scholar · View at Scopus
  116. R. Anderson and T. Prolla, “PGC-1α in aging and anti-aging interventions,” Biochimica et Biophysica Acta, vol. 1790, no. 10, pp. 1059–1066, 2009. View at Publisher · View at Google Scholar · View at Scopus
  117. C. Handschin, Y. M. Kobayashi, S. Chin, P. Seale, K. P. Campbell, and B. M. Spiegelman, “PGC-1α regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy,” Genes and Development, vol. 21, no. 7, pp. 770–783, 2007. View at Publisher · View at Google Scholar · View at Scopus
  118. T. Wenz, F. Diaz, D. Hernandez et al., “Activation of the PPAR/PGC-1a pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy,” Journal of Applied Physiology, vol. 106, pp. 1712–1719, 2008. View at Google Scholar
  119. B. H. Goodpaster, C. L. Carlson, M. Visser et al., “Attenuation of skeletal muscle and strength in the elderly: the health ABC study,” Journal of Applied Physiology, vol. 90, no. 6, pp. 2157–2165, 2001. View at Google Scholar · View at Scopus
  120. M.-Y. Song, E. Ruts, J. Kim, I. Janumala, S. Heymsfield, and D. Gallagher, “Sarcopenia and increased adipose tissue infiltration of muscle in elderly African American women,” American Journal of Clinical Nutrition, vol. 79, no. 5, pp. 874–880, 2004. View at Google Scholar · View at Scopus
  121. M. Zamboni, G. Mazzali, F. Fantin, A. Rossi, and V. di Francesco, “Sarcopenic obesity: a new category of obesity in the elderly,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 18, no. 5, pp. 388–395, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. J. E. Morley, R. N. Baumgartner, R. Roubenoff, J. Mayer, and K. S. Nair, “Sarcopenia,” Journal of Laboratory and Clinical Medicine, vol. 137, no. 4, pp. 231–243, 2001. View at Publisher · View at Google Scholar · View at Scopus
  123. R. J. Roth, A. M. Le, L. Zhang et al., “MAPK phosphatase-1 facilitates the loss of oxidative myofibers associated with obesity in mice,” Journal of Clinical Investigation, vol. 119, no. 12, pp. 3817–3829, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. E. J. Anderson, M. E. Lustig, K. E. Boyle et al., “Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans,” Journal of Clinical Investigation, vol. 119, no. 3, pp. 573–581, 2009. View at Publisher · View at Google Scholar · View at Scopus
  125. C. Bonnard, A. Durand, S. Peyrol et al., “Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice,” Journal of Clinical Investigation, vol. 118, no. 2, pp. 789–800, 2008. View at Publisher · View at Google Scholar · View at Scopus
  126. Z. Arany, S. Y. Foo, Y. Ma et al., “HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α,” Nature, vol. 451, no. 7181, pp. 1008–1012, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. C. Handschin, S. Chin, P. Li et al., “Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1α muscle-specific knock-out animals,” Journal of Biological Chemistry, vol. 282, no. 41, pp. 30014–30021, 2007. View at Publisher · View at Google Scholar · View at Scopus
  128. S. Crunkhorn, F. Dearie, C. Mantzoros et al., “Peroxisome proliferator activator receptor γ coactivator-1 expression is reduced in obesity: potential pathogenic role of saturated fatty acids and p38 mitogen-activated protein kinase activation,” Journal of Biological Chemistry, vol. 282, no. 21, pp. 15439–15450, 2007. View at Publisher · View at Google Scholar · View at Scopus
  129. T. Wenz, S. G. Rossi, R. L. Rotundo, B. M. Spiegelman, and C. T. Moraes, “Increased muscle PGC-1α expression protects from sarcopenia and metabolic disease during aging,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 48, pp. 20405–20410, 2009. View at Publisher · View at Google Scholar · View at Scopus
  130. Z. Arany, “PGC-1 coactivators and skeletal muscle adaptations in health and disease,” Current Opinion in Genetics and Development, vol. 18, no. 5, pp. 426–434, 2008. View at Publisher · View at Google Scholar · View at Scopus